Cargando…
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
The protein tyrosine phosphatase Src homology phosphotyrosyl phosphatase 2 (SHP2) is implicated in various cancers, and targeting SHP2 has become a promising therapeutic approach. We herein described a robust cross-validation high-throughput screening protocol that combined the fluorescence-based en...
Autores principales: | Song, Yihui, Zhao, Min, Wu, Yahong, Yu, Bin, Liu, Hong-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982506/ https://www.ncbi.nlm.nih.gov/pubmed/33777680 http://dx.doi.org/10.1016/j.apsb.2020.10.021 |
Ejemplares similares
-
Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2
por: Chen, Chuan, et al.
Publicado: (2015) -
Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD–Driven AML
por: Pfeiffer, Anamarija, et al.
Publicado: (2022) -
A Fully Automated High-Throughput Flow Cytometry Screening System Enabling Phenotypic Drug Discovery
por: Joslin, John, et al.
Publicado: (2018) -
Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells
por: Raveendra-Panickar, Dhanya, et al.
Publicado: (2021) -
The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines
por: Ghemrawi, Rose, et al.
Publicado: (2022)